Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Precigen (Nasdaq: PGEN) announced that Helen Sabzevari, PhD, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026 at 7:30 AM PT. Dr. Sabzevari will also join a fireside chat hosted by commercialization partner Eversana on January 12, 2026 at 10:30 AM PT during the Biotech Showcase (January 12–14, 2026).

Investors and other participants may view event details in the company’s Events & Presentations section at the investor website.

Key Figures

Q3 2025 Revenue $2.9M Reported in Q3 2025 10-Q

Q3 Net Loss $146.3M Q3 2025 net loss driven by warrant liability change

Cash & Investments $123.6M Balance as of Sept 30, 2025 from 10-Q

Senior Term Loan $100.0M Five-year secured term loan supporting PAPZIMEOS launch

Non-dilutive Facility $125M Credit facility size announced Sept 3, 2025

SG&A Expense $24.0M Q3 2025 SG&A tied to launch preparation

Complete Response Rate 83% 15 of 18 PAPZIMEOS responders in long-term follow-up

Shares Outstanding 353,810,556 Common shares as of Sept 30, 2025

Market Reality Check

$4.55 Last Close

Volume Volume 2,768,591 is 0.54x the 20-day average low

Technical Price 4.28 is trading above 200-day MA of 2.68 before this conference news

Peers on Argus

PGEN is up 2.39% with mixed peer moves: ZYME up 1.91%, while GPCR and RCUS are down 2.36% and 2.18%; NTLA is slightly down and TRML is flat, pointing to stock-specific strength rather than a broad biotech move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 13	Earnings & updates	Positive	-4.0%	Q3 2025 results and business update following full FDA approval of PAPZIMEOS.
Nov 06	Earnings date	Neutral	-0.5%	Announcement of upcoming Q3 2025 results call and business update schedule.
Oct 13	Clinical data update	Positive	+2.9%	Long-term PAPZIMEOS follow-up showing durable complete responses and reduced surgeries.
Sep 03	Financing	Positive	-0.2%	Up to $125M non-dilutive credit facility to support PAPZIMEOS commercialization.
Aug 25	Conferences	Positive	-4.8%	Participation in virtual fireside chats focused on newly FDA-approved RRP therapy.

Pattern Detected

Recent history shows frequent negative price reactions to positive or neutral updates, with only one of the last five news events seeing a clearly aligned positive move.

Recent Company History

Over the last several months, Precigen’s key developments centered on PAPZIMEOS and its commercialization. An August 2025 FDA approval and later long‑term follow‑up data with durable responses in RRP supported the clinical story, while a $125M non‑dilutive credit facility and Q3 2025 results highlighted the shift to a commercial model. Despite these milestones, shares often traded down after updates. Today’s conference participation fits into a pattern of active investor engagement following commercialization progress.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-08-19

An effective Form S-3 shelf filed on 2025-08-19 registers secondary sales of up to 143,809,489 common and 79,000 preferred shares for selling stockholders, with the company receiving no proceeds. This structure enables existing holders to sell via multiple methods without direct capital raised by Precigen.

Market Pulse Summary

This announcement highlights Precigen’s participation in the 44th J.P. Morgan Healthcare Conference and related events, underscoring active outreach as it advances precision medicines in immuno-oncology, autoimmune disorders, and infectious diseases. In the past six months, catalysts have included PAPZIMEOS approval, commercialization financing, and mixed post-news price reactions. Investors may focus on updated launch metrics, financial runway from prior facilities, and any strategic disclosures made during these conference presentations.

Key Terms

biopharmaceutical medical

"Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

immuno-oncology medical

"therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

autoimmune disorders medical

"core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases."

Autoimmune disorders are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs instead of protecting them, causing chronic inflammation and damage. For investors, they matter because they drive demand for long-term treatments, influence the commercial prospects of drugs and diagnostic tests, and affect healthcare costs and regulatory attention—think of the immune system as a home security system that wrongly targets the house it’s supposed to protect.

infectious diseases medical

"therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases."

Infectious diseases are illnesses caused by germs—like bacteria, viruses, fungi or parasites—that can spread between people, animals or through contaminated surfaces. For investors they matter because outbreaks and ongoing transmission change demand for medical treatments, vaccines and diagnostics, alter healthcare costs and regulatory focus, and can disrupt supply chains and consumer behavior much like a sudden storm changes travel and commerce.

AI-generated analysis. Not financial advice.

GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President and Chief Executive Officer of Precigen, will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026 in San Francisco, California. Dr. Sabzevari's company presentation is scheduled for Thursday, January 15, 2026 at 7:30 AM PT.

In addition, Dr. Sabzevari will participate in a fireside chat hosted by the Company's commercialization operations partner, Eversana, on Monday, January 12, 2026 at 10:30 AM PT at the Biotech Showcase, which runs January 12–14, 2026 in San Francisco.

Participants may view details for these events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision^®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company's other product candidates, the timing of clinical trials and their results, the Company's ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com

Media Contact:
Donelle M. Gregory
press@precigen.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302652709.html

SOURCE Precigen, Inc.

FAQ

When will Precigen (PGEN) present at the 44th Annual J.P. Morgan Healthcare Conference?

Precigen will present on January 15, 2026 at 7:30 AM PT.

What time is the Precigen (PGEN) fireside chat with Eversana at Biotech Showcase?

The fireside chat is scheduled for January 12, 2026 at 10:30 AM PT.

Where can investors watch Precigen (PGEN) presentations from J.P. Morgan on January 15, 2026?

Investors can view event details and any webcast information in the company’s Events & Presentations section on the investor website.

Which Precigen executive will speak at J.P. Morgan 2026 and Biotech Showcase 2026?

Helen Sabzevari, PhD, President and CEO of Precigen, will present and participate in the fireside chat.

What dates does the Biotech Showcase and J.P. Morgan Healthcare Conference cover in January 2026?

The Biotech Showcase runs January 12–14, 2026, and the J.P. Morgan Healthcare Conference runs January 12–15, 2026.